Acute mountain sickness is a syndrome that occurs when unacclimatized persons ascend rapidly to high altitudes. It is postulated that cerebral edema causes its symptoms. Since dexamethasone is useful in treating some forms of cerebral edema, we investigated its role in the prevention of acute mountain sickness. Using a double-blind crossover design, we exposed eight young men to a simulated altitude of 4570 m (15,000 ft) on two occasions. By random assignment, each subject received dexamethasone (4 mg every 6 hours) or placebo for 48 hours before and throughout the 42-hour exposure. The presence of symptoms of acute mountain sickness was established by two methods: a questionnaire and an interview by a physician. Dexamethasone significantly reduced the symptoms of acute mountain sickness. During dexamethasone treatment, the cerebral-symptom score (mean +/- S.E.) decreased from 1.09 +/- 0.18 to 0.26 +/- 0.08, and the respiratory-symptom score decreased from 0.64 +/- 0.09 to 0.31 +/- 0.06 (both, P less than 0.05). As judged by the interviewing physician, the symptom score decreased from 1.10 +/- 0.11 to 0.28 +/- 0.07 (P = 0.01). We conclude that dexamethasone may be effective in preventing the symptoms of acute mountain sickness.
This article has been cited by other articles:
Schoene, R. B.
(2008). Illnesses at High Altitude. Chest
134: 402-416
[Abstract][Full Text]
Spooner, L. M., Olin, J. L., Debellis, R. J.
(2007). Pharmacotherapy of High-Altitude Illness. AMERICAN JOURNAL OF LIFESTYLE MEDICINE
1: 129-141
[Abstract]
Maggiorini, M., Brunner-La Rocca, H.-P., Peth, S., Fischler, M., Bohm, T., Bernheim, A., Kiencke, S., Bloch, K. E., Dehnert, C., Naeije, R., Lehmann, T., Bartsch, P., Mairbaurl, H.
(2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial.. ANN INTERN MED
145: 497-506
[Abstract][Full Text]
Moayeri, M., Webster, J. I., Wiggins, J. F., Leppla, S. H., Sternberg, E. M.
(2005). Endocrine Perturbation Increases Susceptibility of Mice to Anthrax Lethal Toxin. Infect. Immun.
73: 4238-4244
[Abstract][Full Text]
Van Osta, A., Moraine, J.-J., Melot, C., Mairbaurl, H., Maggiorini, M., Naeije, R.
(2005). Effects of High Altitude Exposure on Cerebral Hemodynamics in Normal Subjects. Stroke
36: 557-560
[Abstract][Full Text]
Kodama, T., Shimizu, N., Yoshikawa, N., Makino, Y., Ouchida, R., Okamoto, K., Hisada, T., Nakamura, H., Morimoto, C., Tanaka, H.
(2003). Role of the Glucocorticoid Receptor for Regulation of Hypoxia-dependent Gene Expression. J. Biol. Chem.
278: 33384-33391
[Abstract][Full Text]
Ellsworth, A.
(2003). Pharmacotherapy for Altitude-Related Illness. Journal of Pharmacy Practice
16: 68-75
[Abstract]
Hackett, P. H., Roach, R. C.
(2001). High-Altitude Illness. NEJM
345: 107-114
[Full Text]
Dumont, L., Mardirosoff, C., Tramèr, M. R
(2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ
321: 267-272
[Abstract][Full Text]
Poncet, L., Pequignot, J.-M., Cottet-Emard, J.-M., Dalmaz, Y., Denoroy, L.
(1999). Altered daily rhythms of brain and pituitary indolamines and neuropeptides in long-term hypoxic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol.
277: R66-R75
[Abstract][Full Text]
Keller, H.-R., Maggiorini, M., Bartsch, P., Oelz, O.
(1995). Simulated descent v dexamethasone in treatment of acute mountain sickness: a randomised trial. BMJ
310: 1232-1235
[Abstract][Full Text]
Previous
